Src Family Kinase Inhibition as a Novel Strategy to Augment Melphalan-Based Regional Chemotherapy of Advanced Extremity Melanoma

Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma

(2012) R. S. Turley et al.   CLINICAL CANCER RESEARCH

Molecular testing in malignant melanoma

(2012) Allie H. Grossmann et al.   DIAGNOSTIC CYTOPATHOLOGY

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

(2011) A P Algazi et al.   BRITISH JOURNAL OF CANCER

Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors

(2011) J. C. Montero et al.   CLINICAL CANCER RESEARCH

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

In vitro studies of dasatinib, its targets and predictors of sensitivity

(2011) Lucia B. Jilaveanu et al.   Pigment Cell & Melanoma Research

Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma

(2010) Hiroaki Toshimitsu et al.   ANNALS OF SURGICAL ONCOLOGY

Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics

(2010) Scott E. Woodman et al.   BIOCHEMICAL PHARMACOLOGY

A phase 2 trial of dasatinib in advanced melanoma

(2010) Harriet M. Kluger et al.   CANCER

Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy

(2010) C. K. Augustine et al.   MOLECULAR CANCER THERAPEUTICS

Gene Expression Signatures as a Guide to Treatment Strategies for In-Transit Metastatic Melanoma

(2010) Christina K. Augustine et al.   MOLECULAR CANCER THERAPEUTICS

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma

(2009) Jade Homsi et al.   MELANOMA RESEARCH

Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

(2009) S. E. Woodman et al.   MOLECULAR CANCER THERAPEUTICS

Src kinases as therapeutic targets for cancer

(2009) Lori C. Kim et al.   Nature Reviews Clinical Oncology

Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion

(2008) Georgia M. Beasley et al.   ANNALS OF SURGICAL ONCOLOGY

Phase II trial of imatinib mesylate in patients with metastatic melanoma

(2008) K B Kim et al.   BRITISH JOURNAL OF CANCER

Targeting N-Cadherin Enhances Antitumor Activity of Cytotoxic Therapies in Melanoma Treatment

(2008) C. K. Augustine et al.   CANCER RESEARCH

Major Response to Imatinib Mesylate in KIT-Mutated Melanoma

(2008) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines

(2008) Alex J Eustace et al.   Journal of Translational Medicine